First Tracks Biotherapeutics, Inc.
corporate_fare Company Profile
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for TRAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-12, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for TRAX spans 8-K, 424B3, 10-Q, S-1.
Recent high-impact activity:
- First Tracks Q2: FDA Fast Track for ANB033, Cash Runway Extended to Q2 2028
- First Tracks Posts Q2 Loss, FDA Fast Track for ANB033, Data Readouts Set Through 2027
- Selling Stockholders to Resell 10.5M Shares, Adding Significant Market Overhang
- First Tracks Biotherapeutics Reports Q1 Results, Confirms $180M Capital Infusion Post-Spin-Off, and Advances Clinical Pipeline
- First Tracks Bio Receives Positive FDA Feedback for Rosnilimab, Explores Strategic Options
Short Interest & Short Volume
7.50 days to coverFINRA reported short interest of 4,500,079 shares in TRAX as of the September 15, 2026 settlement, a 11.7% increase from the prior period — about 7.5 days to cover at its recent average daily volume. On October 2, 2026, 45.8% of TRAX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TRAX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-13.
Resale Registration for 10.5M Shares · Incorporates Q2 2026 10-Q
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →